While the Biosimilar market is expected to reach $20B by 2020, four factors will play a major influence on just how quickly the biosimilar market will grow: patent expirations, regulatory pathways, development challenges and viability of a commercial model.

Chairperson:
Charles Squires, Vice President, Discovery & Partnerships, Pfenex

Panelists:
Cyrus Karkaria, President, Biotech Division, Lupin
Sophie Opdyke, Vice President, Commercial Development Biosimilars, Pfizer
Anand Iyer, Chief Executive Officer, Agila Biotech